Telpha Inc Pharmaceutical Import Profile — Cambodia (DGFT 2022–2026)

Name: Telpha Inc Pharmaceutical Import Records from India — 2 Products, $4.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Telpha Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $4.5M Trade | TransData Nexus

Telpha Inc

Pharmaceutical Importer · Cambodia · Cardiovascular Focus · $4.5M Total Trade · DGFT Verified

Telpha Inc is a pharmaceutical importer based in Cambodia with a total trade value of $4.5M across 2 products in 1 therapeutic categories. Based on 147 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Telpha Inc sources from 24 verified Indian suppliers, with Global Pharma Healthcare Private Limited accounting for 18.6% of imports.

Telpha Inc — Import Portfolio & Supplier Network

Telpha Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Telpha Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Global Pharma Healthcare Private Limited	$1.5M	269	18.6%
Rainbow Life Sciences Private Limited	$1.1M	81	12.9%
Telphacare India Private Limited	$886.9K	132

What Formulations Does Telpha Inc Import?

Formulation	Value	Ships
Amlotel (amlodipine 5 MG and	$145.1K	5
Harmless medicines adipin-5 amlodipine	$138.9K	5
Human normal albumin 20% 50ML (alburel	$100.0K	2
Harmless medicines,adipin-10	$88.7K	5
Isoflurane 250ML other desc.as per invoice attch.green card no.420/vsez	$85.0K	2
Sevoflurane 250 ML other desc.as per invoice attch.green card no.420/vsez	$80.1K	2
Harmless medicines,adipin-5 amlodipine	$75.7K	5
Cefixime tablets USP 200 MG (cefixime-m)	$75.4K	2
Pirojet iv 1ooml - batch no: 2ub414	$64.8K	2
Pharmaceutical ingredient of indian	$61.1K	4
Isoflurane 250ML other desc as per invoice attch green card no 420 vsez dt 10 05	$60.7K	2
Harmless medicines,adipin-5 amlodipine 5MG tablet (1x10x10)	$58.1K	4
Harmless medicines adipin-5 amlodipine 5MG tablet unit- 1x10x10 qty-11280 .	$51.5K	3
Sitagliptin tablets USP 100MG	$51.1K	2
Harmless medicines,adipin 10	$50.0K	1

Telpha Inc imports 804 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amlodipine	Cardiovascular	$3.1M	120	0.0%	15
2	Telmisartan	Cardiovascular	$1.4M	27	0.0%	13

Telpha Inc imports 2 pharmaceutical products across 1 categories into Cambodia totaling $4.5M.

Telpha Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Telpha Inc, established in May 2008, is a prominent pharmaceutical organization headquartered in Phnom Penh, Cambodia. The company specializes in providing comprehensive marketing services for healthcare therapies, aiming to enhance the quality of life for its customers. Over the past two decades, Telpha has emerged as a leading entity in Cambodia's pharmaceutical sector, boasting a substantial customer base and nationwide coverage.

Operating in multiple countries, including India, Cambodia, Myanmar, and Vietnam, Telpha focuses on the development and marketing of specialized portfolios of healthcare products, branded generics, and a range of over-the-counter (OTC) products. The company's mission is to be a global pharmaceutical leader with a focus on innovative marketing of specialty pharmaceuticals.

2Distribution Network

Telpha Inc's distribution network is robust, ensuring efficient delivery of pharmaceutical products across Cambodia. While specific warehouse locations are not publicly disclosed, the company's strategic operations in Cambodia, Myanmar, and Vietnam suggest a well-established logistics framework capable of supporting its extensive product portfolio. This infrastructure enables Telpha to maintain a strong presence in the Southeast Asian market, facilitating timely and reliable distribution to meet the needs of its diverse clientele.

3Industry Role

In Cambodia's pharmaceutical supply chain, Telpha Inc functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from various international suppliers, including India, and distributes these products to retail pharmacies, hospitals, and other healthcare institutions across Cambodia. This role positions Telpha as a key player in ensuring the availability of essential medications and healthcare products within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Telpha Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Telpha Inc's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India stands at $4.5 million USD, encompassing 147 shipments and 804 unique formulations across one therapeutic category. The top five products imported include Amlodipine ($3.1 million, Rank #15, 0.0% share) and Telmisartan ($1.4 million, Rank #13, 0.0% share).

This sourcing pattern indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities and competitive pricing. However, the lack of diversification in supplier base may expose Telpha to risks associated with supply chain disruptions, such as regulatory changes or production issues in India. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent volume of imports over the years. Nonetheless, the absence of alternative suppliers could pose challenges in mitigating potential disruptions.

2Supply Chain Resilience

Telpha Inc's supply chain resilience is closely tied to its reliance on Indian pharmaceutical manufacturers. The company's import data indicates a concentration of suppliers, with the top five accounting for a substantial portion of the total import value. This reliance suggests that while Telpha benefits from established relationships and potentially favorable terms with these suppliers, it may face challenges in the event of supply chain disruptions. The lack of backup suppliers and limited formulation diversity could impact the company's ability to adapt to unforeseen circumstances. Additionally, the exposure to shipping routes from India introduces potential vulnerabilities related to geopolitical factors and logistical challenges. Ensuring the regulatory compliance of key suppliers is crucial to maintain uninterrupted supply and adhere to Cambodia's pharmaceutical import regulations.

Importing Pharmaceuticals into Cambodia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Cambodia

1Regulatory Authority & Framework

In Cambodia, the Ministry of Health (MoH) serves as the primary regulatory authority overseeing the pharmaceutical sector. The MoH is responsible for the regulation, importation, and distribution of pharmaceutical products within the country. The legal framework governing pharmaceutical imports includes the Law on the Management of Pharmaceuticals, which outlines the procedures and conditions for the production, import, export, and trade of pharmaceuticals. This legislation mandates that all pharmaceutical products imported into Cambodia must be registered with the MoH and comply with established standards to ensure public health and safety. (wipo.int)

2Import Licensing & GMP

Import licensing for pharmaceuticals in Cambodia is administered by the MoH. Companies seeking to import pharmaceutical products must obtain an import certificate, which requires compliance with specific technical procedures and conditions. Additionally, the MoH recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their products meet these standards to facilitate the import process and maintain product quality. (cambodiantr.gov.kh)

Quality & Labeling

Telpha Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Telpha Inc's product strategy focuses on therapeutic areas such as cardiology, gastroenterology, hepatology, diabetology, oncology, and critical care. The company's import data indicates a concentration in the cardiovascular category, with products like Amlodipine and Telmisartan being significant imports. This focus aligns with the growing prevalence of cardiovascular diseases in Cambodia and the demand for effective treatments. By importing these specific therapeutic areas, Telpha aims to address critical health needs and enhance patient outcomes in the region.

2Sourcing Profile

Telpha Inc's sourcing strategy is centered on importing generic pharmaceutical formulations from India. The company's import data reveals a preference for specific formulations, particularly in the cardiovascular category. This approach allows Telpha to offer cost-effective treatment options to the Cambodian market while maintaining a focus on quality. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a strategic partner for Telpha's procurement needs.

3Market Positioning

Based on its product mix, Telpha Inc serves multiple segments of the Cambodian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential therapeutic areas and its extensive distribution network enable it to meet the diverse needs of these segments effectively. By providing a range of pharmaceutical products, Telpha positions itself as a comprehensive supplier committed to improving healthcare outcomes across Cambodia.

Seller's Guide — How to Become a Supplier to Telpha Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Telpha Inc. The company's concentrated sourcing strategy indicates a potential openness to expanding its supplier base, especially if new suppliers can offer competitive pricing and high-quality products. Gaps in Telpha's current sourcing include a limited diversification of suppliers and formulations. Indian exporters can explore these opportunities by introducing alternative products or formulations that align with Cambodia's market needs and regulatory requirements.

2Requirements & Qualifications

Indian exporters seeking to supply Telpha Inc and the Cambodian market must adhere to specific certifications and quality standards. Products must be registered with the Cambodian Ministry of Health, requiring compliance with GMP or ISO certifications from recognized international bodies. Additionally, exporters must provide a free sale certificate, a letter of authorization, and the product's manual. Ensuring that products have at least 18 months of validity before the expiry date is also a critical requirement.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Telpha Inc

What products does Telpha Inc import from India?

Telpha Inc imports 2 pharmaceutical products across 1 categories. Top imports: Amlodipine ($3.1M), Telmisartan ($1.4M).

Who supplies pharmaceuticals to Telpha Inc from India?

Telpha Inc sources from 24 verified Indian suppliers. The primary supplier is Global Pharma Healthcare Private Limited (18.6% of imports, $1.5M).

What is Telpha Inc's total pharmaceutical import value?

Telpha Inc's total pharmaceutical import value from India is $4.5M, based on 147 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Telpha Inc focus on?

Telpha Inc imports across 1 categories. The largest: Cardiovascular (100.0%).

Get Full Telpha Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.